ClinicalTrials.gg
TerminatedNCT01533714Updated May 20, 2022Results posted

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

A Phase 2 interventional study of CDP6038 (olokizumab) in Rheumatoid Arthritis, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 32 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision to out-license the compound for further development

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
8th of 10
103 · median 206
Started
2012
the only one that year
Phase 2
4 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
UCB BIOSCIENCES, Inc.

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (RA) who completed study RA0083 [NCT01463059].

Read the detailed description

Male and female subjects were randomized in a multi-center, open-label, follow-up study to assess the long-term safety and efficacy of a subcutaneous dose of 120 mg CDP6038 (olokizumab), every 2 weeks (q2w), for the treatment of active RA.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • Monoclonal antibody
  • Interleukin-6
  • Olokizumab
  • CDP6038
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the RA0083 [NCT01463059] study (Week 12 Visit)
  • Must have maintained their stable dose (and route) of methotrexate (MTX) between 6 to 16 mg/week in Japan or 7.5 to 20 mg/week in Korea and Taiwan in RA0083 [NCT01463059], and plan to maintain this same dose and route of administration for at least 12 weeks
  • Female subjects must be either for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of

Exclusion criteria

Exclusion Criteria:

  • Have an ongoing SAE from the RA0083 [NCT01463059] study
  • Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks
  • Have evidence of active or latent tuberculosis (TB)
  • Subject is receiving any biologic response modifier or synthetic disease-modifying antirheumatic drug (DMARD) other than MTX
  • Subject has planned surgery during the first 12 weeks of the study
  • Subjects who tested positive for core antibody (HBcAb) and/or hepatitis B surface antibody (HBsAb) at Screening in RA0083 [NCT01463059] and who subsequently test positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) at Week 12 of RA0083 [NCT01463059]
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    CDP6038 (olokizumab)

    CDP6038 (olokizumab) 120 mg: subcutaneous injections at q2w (every two weeks). RA0089 is a single arm study, however, analysis will be presented according to the original treatment arms of the parent study NCT01463059 (RA0083).

    Biological: CDP6038 (olokizumab)

Interventions

  • Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection

06

What researchers measure

Primary outcomes

  1. Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0089 and within 30 days after the last dose.

    Time frame: From Baseline (Week 0 of Study RA0089) until 30 days after the last dose (maximum up to 562 days)

Secondary outcomes

  1. Change From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089

    DAS28(CRP) was calculated using tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), and CRP as per formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: •TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. 28 joints included shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores greater than (\>) 5.1 correspond with active disease, scores less than (\<) 3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)

  2. Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)

  3. Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  4. Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 96 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no results data are available for analysis at the Week 96 time point and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  5. The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

    ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)

  6. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

    ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)

  7. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

    ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  8. The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

    ACR20: at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  9. The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

    ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)

  10. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

    ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)

  11. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

    ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  12. The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

    ACR50:atleast 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  13. The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

    ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)

  14. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

    ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)

  15. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

    ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  16. The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

    ACR70:atleast 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  17. Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

    Time frame: Week 12 (Study RA0089)

  18. Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

    Time frame: Week 24 (Study RA0089)

  19. Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

    Time frame: Week 48 (Study RA0089)

  20. Percentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Week 96 (Study RA0089)

  21. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) less than or equal to (≤) 3.2 were reported.

    Time frame: Week 12 (Study RA0089)

  22. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.

    Time frame: Week 24 (Study RA0089)

  23. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.

    Time frame: Week 48 (Study RA0089)

  24. Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0089

    DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Week 96 (Study RA0089)

  25. Change From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089

    CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  26. Change From Baseline (Week 0 of Study RA0083) CDAI at Week 96 of Study RA0089

    CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  27. Change From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089

    SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)

  28. Change From Baseline (Week 0 of Study RA0083) in the SDAI at Week 96 of Study RA0089

    SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), as per formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

    Time frame: Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

  29. Plasma Concentration of CDP6038 (Olokizumab) at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

    The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.

    Time frame: Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

  30. Plasma Concentration of Anti-CDP6038 (Olokizumab) Antibodies at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96 and 120

    The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.

    Time frame: Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

07

Results

Posted May 17, 2022
Limitations and caveats
The clinical trial was terminated early following a strategic UCB decision to out-license the study drug for further development. No data were collected at Week 96 or beyond; no analysis was performed on study drug plasma levels or antibodies.

Participant flow

The present study was an open-label extension to study RA0083 (NCT01463059). Subjects completing the 12-week treatment period of study RA0083 had the opportunity to participate in this study. First subject enrolled: 26 January 2012. Last subject completed: 27 November 2013.

Participant flow — Overall Study
MilestoneRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Started101511152824
Completed10127112121
Not completed034473
Withdrew: Adverse event012221
Withdrew: Lack of efficacy000001
Withdrew: Withdrawal by subject010110
Withdrew: Exclusion criteria010000
Withdrew: Positive for purified protein derivative001010
Withdrew: Withdrawal criteria001031
Withdrew: Ineligibility reason000100

Outcome measures

PrimaryTotal Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

Reported TEAEs included adverse events that started or worsened after the first dose of CDP6038 (olokizumab) in Study RA0089 and within 30 days after the last dose.

Time frame:
From Baseline (Week 0 of Study RA0089) until 30 days after the last dose (maximum up to 562 days)
Reported as:
Count of participants · Participants
Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
ParticipantsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Total Number of Subjects With Treatment-emergent Adverse Events (TEAEs)81310122522
SecondaryChange From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089

DAS28(CRP) was calculated using tender/painful joint count (TJC) and swollen joint count (SJC) from 28 joints, Patient's Global Assessment of Disease Activity (PtGADA)-Visual Analog Scale (VAS), and CRP as per formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: •TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. 28 joints included shoulders, elbows, wrists; metacarpophalangeal (MCP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores greater than (\>) 5.1 correspond with active disease, scores less than (\<) 3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089
units on a scaleRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Change From Baseline (Week 0 of Study RA0083) in the Disease Activity Score-28-joint Count (C-reactive Protein) (DAS28[CRP]) at Week 12 of Study RA0089-2.9618 ± 1.05692-2.5358 ± 1.11550-2.9758 ± 1.23346-2.7948 ± 1.28792-2.6837 ± 0.80614-2.5902 ± 1.06296
SecondaryChange From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089
units on a scaleRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 24 of Study RA0089-2.6916 ± 0.75807-3.3277 ± 1.05841-3.3523 ± 0.74516-2.8884 ± 1.43276-3.0176 ± 0.82217-2.8235 ± 0.99271
SecondaryChange From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089
units on a scaleRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Change From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 48 of Study RA0089-2.6243 ± 1.52735-3.2720 ± 0.97343-3.2397 ± 0.85356-2.9625 ± 1.16236-2.4750 ± 1.31771-3.2211 ± 0.45471
SecondaryChange From Baseline (Week 0 of Study RA0083) in DAS28(CRP) at Week 96 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. A negative change in DAS28(CRP) score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no results data are available for analysis at the Week 96 time point and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryThe American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, Physician's Global Assessment of Disease Activity (PhGADA)-VAS, Patient's Assessment of Arthritis Pain (PAAP)-VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI) and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
Reported as:
Number · Percentage of responders
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The American College of Rheumatology (ACR) 20% (ACR20) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089100.060.081.871.464.370.8
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA008960.046.781.857.171.466.7
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

ACR20 represents at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA008920.013.354.521.421.433.3
SecondaryThe ACR20 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

ACR20: at least 20% improvement from Baseline in TJC (68 joints) + SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryThe ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR 50% (ACR50) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA008970.040.054.542.942.950.0
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA008940.040.063.657.142.945.8
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

ACR50 represents at least 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA008920.013.345.514.317.929.2
SecondaryThe ACR50 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

ACR50:atleast 50% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryThe ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089

ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 12 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR 70% (ACR70) Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 12 of Study RA008930.026.727.321.417.929.2
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089

ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 24 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 24 of Study RA008910.020.054.542.932.125.0
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089

ACR70 represents at least 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Number · Percentage of responders
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA0089
Percentage of respondersRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
The ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 48 of Study RA008910.013.318.214.37.116.7
SecondaryThe ACR70 Improvement Criteria Response Rate From Baseline (Week 0 of Study RA0083) at Week 96 of Study RA0089

ACR70:atleast 70% improvement from Baseline in TJC (68 joints) + in SJC (66 joints) + in at least 3 of 5 core set measures: PtGADA-VAS, PhGADA-VAS, PAAP-VAS, HAQ-DI and CRP. Assessments: • TJC and SJC: same 2-point scale (0=absent;1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms;100=very poor, severe symptoms). • PhGADA: 100 mm VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • PAAP: 100 mm VAS (0=no pain;100=most severe pain). • HAQ-DI assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. • CRP in mg/L. Missing values were considered as non-responding status. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

Time frame:
Week 12 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) <2.6 at Week 12 of Study RA008950.0064.2970.0053.8543.4839.13
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

Time frame:
Week 24 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) <2.6 at Week 24 of Study RA008950.0077.7880.0054.5559.0940.91
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported.

Time frame:
Week 48 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) <2.6 at Week 48 of Study RA008966.67100.0083.33100.0042.8655.56
SecondaryPercentage of Subjects With DAS28(CRP) <2.6 at Week 96 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) \<2.6 were reported. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) less than or equal to (≤) 3.2 were reported.

Time frame:
Week 12 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 12 of Study RA0089100.0071.4380.0069.2378.2665.22
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.

Time frame:
Week 24 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 24 of Study RA008987.50100.0090.0081.8272.7377.27
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Percentage of participants with DAS28(CRP) ≤3.2 were reported.

Time frame:
Week 48 (Study RA0089)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA0089
Percentage of subjectsRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Percentage of Subjects With DAS28(CRP) ≤3.2 at Week 48 of Study RA008966.67100.00100.00100.0071.4377.78
SecondaryPercentage of Subjects With DAS28(CRP) ≤3.2 at Week 96 of Study RA0089

DAS28(CRP) was calculated using the TJC and SJC from 28 joints, the PtGADA-VAS, andCRP according to the formula: DAS28(CRP)=0.56 \* (TJC)\^1/2 + 0.28 \* (SJC)\^1/2 + 0.36 \* ln(CRP\[mg/L\]+1) + 0.014 \* PtGADA + 0.96 Assessments: • TJC and SJC: assessed on same 2-point scale (0=absent; 1=present). • PtGADA: 100 mm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • CRP value calculated in mg/L. The 28 joints included shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of hands; and knees. Scores on DAS28(CRP) range from 0 to approximately 10, where scores \>5.1 correspond with active disease, scores \<3.2 correspond with well controlled disease, and scores \<2.6 correspond with remission or similar. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryChange From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089

CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089
units on a scaleRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Change From Baseline (Week 0 of Study RA0083) in the Clinical Disease Activity Index (CDAI) at Week 48 of Study RA0089-72.0000 ± 86.13362-108.0256 ± 77.85787-95.1667 ± 24.41652-75.2870 ± 46.83603-94.7363 ± 54.63562-99.9744 ± 41.83169
SecondaryChange From Baseline (Week 0 of Study RA0083) CDAI at Week 96 of Study RA0089

CDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS and PhGADA-VAS, according to the following formula: SJC + TJC + PtGADA + PhGADA Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. Total score range is from 0-100, with the high scores representing high disease activity. A negative change in CDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryChange From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089

SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), according to the following formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. The SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 48 (Study RA0089)
Reported as:
Mean · units on a scale
Change From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089
units on a scaleRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
Change From Baseline (Week 0 of Study RA0083) in the Simplified Disease Activity Index (SDAI) at Week 48 of Study RA0089-75.6667 ± 90.23488-130.6923 ± 97.08073-125.1667 ± 48.85659-93.7870 ± 61.23550-113.3077 ± 53.87161-127.8633 ± 38.49694
SecondaryChange From Baseline (Week 0 of Study RA0083) in the SDAI at Week 96 of Study RA0089

SDAI was calculated using the TJC (28 joints), SJC (28 joints), PtGADA-VAS, PhGADA-VAS and CRP (mg/dL\]), as per formula: SJC + TJC + PtGADA + PhGADA + CRP (mg/dL) Assessments: • TJC and SJC: assessed on the same 2-point scale (0=absent; 1=present). • PtGADA: 10 cm VAS (0=very good, no symptoms; 100=very poor, severe symptoms). • PhGADA: 10 cm VAS (0=very good, asymptomatic and no limitation of normal activities; 100=very poor, very severe symptoms which were intolerable and inability to carry out all normal activities). • CRP range was from 0 to 10 mg/dL. The 28 joints included the shoulders, elbows, wrists; MCP, thumb IP, and PIP joints of the hands; and the knees. SDAI score ranges from 0 to 86, with higher scores representing worse disease. A negative change in SDAI score indicates an improvement in disease activity. Since the study was terminated early before Week 96, no data was collected and analyzed at the Week 96 and this Outcome Measure has zero total participants analyzed.

Time frame:
Baseline (Week 0 of Study RA0083) and Week 96 (Study RA0089)

Results for this outcome have not been posted.

SecondaryPlasma Concentration of CDP6038 (Olokizumab) at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.

Time frame:
Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

Results for this outcome have not been posted.

SecondaryPlasma Concentration of Anti-CDP6038 (Olokizumab) Antibodies at Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96 and 120

The CDP6038 (olokizumab) plasma levels data were not collected and analyzed. This Outcome Measure therefore has zero total participants analyzed.

Time frame:
Weeks 4, 8, 12, 16, 24, 32, 40, 48, 72, 96, 120

Results for this outcome have not been posted.

Adverse events

Collected over From Baseline (Week 0 of Study RA0089) until 30 days after the last dose (maximum up to 562 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RA0083 CDP6038 (Olokizumab) 120 mg q2w0/10 (0%)1/10 (10%)8/10 (80%)
RA0083 CDP6038 (Olokizumab) 120 mg q4w0/15 (0%)0/15 (0%)13/15 (86.7%)
RA0083 CDP6038 (Olokizumab) 240 mg q4w0/11 (0%)2/11 (18.2%)10/11 (90.9%)
RA0083 CDP6038 (Olokizumab) 60 mg q2w0/15 (0%)2/15 (13.3%)12/15 (80%)
RA0083 CDP6038 (Olokizumab) 60 mg q4w0/28 (0%)5/28 (17.9%)25/28 (89.3%)
RA0083 Placebo0/24 (0%)4/24 (16.7%)21/24 (87.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
HaemorrhoidsGastrointestinal disorders1/100/150/110/150/280/24
Subdural haematomaInjury, poisoning and procedural complications1/100/150/110/150/280/24
Duodenal ulcer haemorrhageGastrointestinal disorders0/100/151/110/150/280/24
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/151/110/150/280/24
GastroenteritisInfections and infestations0/100/150/111/150/280/24
PneumoniaInfections and infestations0/100/150/111/150/280/24
PleurisyRespiratory, thoracic and mediastinal disorders0/100/150/111/150/280/24
CellulitisInfections and infestations0/100/150/110/151/281/24
EpiglottitisInfections and infestations0/100/150/110/150/281/24
Femoral neck fractureInjury, poisoning and procedural complications0/100/150/110/150/281/24
Most frequent other events
Showing 10 of 126
Most frequent other events
EventRA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 Placebo
NasopharyngitisInfections and infestations3/106/152/116/159/288/24
StomatitisGastrointestinal disorders3/102/153/111/152/282/24
GastroenteritisInfections and infestations0/101/153/112/151/280/24
PharyngitisInfections and infestations0/101/153/111/150/280/24
Alanine aminotransferase increasedInvestigations0/100/151/111/150/285/24
Aspartate aminotransferase increasedInvestigations0/100/150/111/150/285/24
Injection site erythemaGeneral disorders2/102/151/110/152/282/24
Injection site indurationGeneral disorders2/100/150/110/150/280/24
Seasonal allergyImmune system disorders2/100/150/111/151/281/24
Herpes zosterInfections and infestations0/103/151/112/150/281/24

Baseline characteristics

Safety Population included all enrolled subjects who received at least 1 injection of CDP6038 (olokizumab) in Study RA0089.

Age, Categorical
Age, Categorical(Participants)RA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 PlaceboTotal
<=18 years0000000
Between 18 and 65 years7111013231882
>=65 years34125621
Sex: Female, Male
Sex: Female, Male(Participants)RA0083 CDP6038 (Olokizumab) 120 mg q2wRA0083 CDP6038 (Olokizumab) 120 mg q4wRA0083 CDP6038 (Olokizumab) 240 mg q4wRA0083 CDP6038 (Olokizumab) 60 mg q2wRA0083 CDP6038 (Olokizumab) 60 mg q4wRA0083 PlaceboTotal
Female712912272188
Male33231315
08

Study locations

32 sites
  • 102
    Chiba, Japan
  • 114
    Fukuoka, Japan
  • 115
    Fukuoka, Japan
  • 113
    Hiroshima, Japan
  • 120
    Kakogawa, Japan
  • 118
    Kumamoto, Japan
  • 116
    Kurume, Japan
  • 122
    Matsuyama, Japan
  • 107
    Nagaoka, Japan
  • 110
    Nagoya, Japan
  • 103
    Narita, Japan
  • 119
    Oita, Japan
  • 112
    Okayama, Japan
  • 100
    Sapporo, Japan
  • 117
    Sasebo, Japan
  • 123
    Tokyo, Japan
  • 101
    Tomakomai, Japan
  • 108
    Tonami, Japan
  • 111
    Tsu, Japan
  • 105
    Yokohama, Japan
  • 104
    Yotukaido, Japan
  • 200
    Daejeon, Korea, Republic of
  • 201
    Jung-Gu, Korea, Republic of
  • 202
    Seongdong-Gu, Korea, Republic of
  • 203
    Seoul, Korea, Republic of
  • 204
    Seoul, Korea, Republic of
  • 301
    Taichung, Taiwan
  • 306
    Taichung, Taiwan
  • 307
    Taichung, Taiwan
  • 302
    Taipei, Taiwan
  • 308
    Taipei, Taiwan
  • 309
    Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2012 to primary completion in Nov 2013, 22 months.

Results were first posted in May 2022, 8 years 5 months after primary completion. A results delay was requested in Aug 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2012
First posted
Feb 15, 2012
StartActual
Jan 26, 2012
Primary completionActual
Nov 27, 2013
CompletionActual
Nov 29, 2013
Results delay requested
Aug 25, 2014
Results first posted
May 17, 2022
Last update
May 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01533714
Collaborators
R-Pharm
Responsible party
Sponsor
First posted
Feb 15, 2012
Start date
Jan 26, 2012
Primary completion
Nov 27, 2013
Completion
Nov 29, 2013
Results posted
May 17, 2022
Last update
May 20, 2022

Study contacts

Tsutomu Takeuchi, Professor
principal investigator · Keio University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion